Join
Live feed
·
PRReleasevia Quantisnow
Rocket Pharmaceuticals Inc. logo

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy

ByQuantisnow·Wall Street's wire, on your screen.
RCKT· Rocket Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RCKT (Rocket Pharmaceuticals Inc.) and more on Quantisnow.